Search results
Heart disease: Millions may no longer get preventive statin therapy
Medical News Today· 15 hours agoAtherosclerotic cardiovascular disease is linked to plaque buildup in blood vessels. It can increase...
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
InvestorPlace· 2 days agoFundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means...
The Shifting Epidemiology of Hypercholesterolemia
MedPage Today· 2 days agoThe epidemiology of hypercholesterolemia has been shifting in recent years. The optimal total cholesterol level is defined as about 150 mg/dL, putting low-density lipoprotein (LDL) cholesterol ...
Ventyx Biosciences stock holds at Neutral amid competitor's trial results By Investing.com
Investing.com· 2 days agoThis drug is seen as a direct rival to Ventyx's own NLRP3 inhibitor, VTX3232. NodThera's NT-0796...
Man died at Tacoma immigration detention center of natural causes, medical examiner says
Tacoma News Tribune via Yahoo News· 4 days agoIn 2006, a 42-year-old man died of coronary artery disease. In 2018, a 40-year-old man held in...
Jun 14 2024 This Week in Cardiology
Medscape· 1 day agoThis podcast is intended for healthcare professionals only. For the week ending June 14.2024, John Mandrola, MD, comments on the following news and...
Statins may help prevent some forms of cancer, study finds
Medical News Today· 7 days agoStatin medications help keep cholesterol levels within a healthy range, but researchers are...
GSA Capital Partners LLP Raises Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
ETF DAILY NEWS· 1 day agoGSA Capital Partners LLP increased its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 1.0% in the 4th quarter, according to its most recent disclosure with the SEC. The ...
Esperion Therapeutics Target of Unusually High Options Trading (NASDAQ:ESPR)
ETF DAILY NEWS· 3 days agoEsperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw some unusual options trading activity on Monday. Investors bought 5,316 call options on the stock. This represents an increase ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $9.33 Consensus Target Price from Analysts
ETF DAILY NEWS· 3 days agoEsperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has earned an average rating of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. Three research ...
